Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1995 1
1997 2
1998 4
1999 3
2000 5
2001 6
2002 7
2003 4
2004 6
2005 7
2006 7
2007 6
2008 3
2009 2
2010 6
2011 7
2012 7
2013 12
2014 12
2015 8
2016 12
2017 20
2018 16
2019 24
2020 21
2021 9
2022 8
2023 16
2024 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Age-related macular degeneration.
Bek T, Sørensen TL. Bek T, et al. Among authors: sorensen tl. Ugeskr Laeger. 2023 Nov 27;185(48):V05230316. Ugeskr Laeger. 2023. PMID: 38018728 Free article. Review. Danish.
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators. Khanani AM, et al. Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19. Ophthalmology. 2024. PMID: 38382813 Free article. Clinical Trial.
Splenic monocytes drive pathogenic subretinal inflammation in age-related macular degeneration.
Roubeix C, Nous C, Augustin S, Ronning KE, Mathis T, Blond F, Lagouge-Roussey P, Crespo-Garcia S, Sullivan PM, Gautier EL, Reichhart N, Sahel JA, Burns ME, Paques M, Sørensen TL, Strauss O, Guillonneau X, Delarasse C, Sennlaub F. Roubeix C, et al. Among authors: sorensen tl. J Neuroinflammation. 2024 Jan 17;21(1):22. doi: 10.1186/s12974-024-03011-z. J Neuroinflammation. 2024. PMID: 38233865 Free PMC article.
Geographic atrophy - Signs, symptoms, and quality of life.
Krogh Nielsen M, Hinnerskov JMV, Sørensen TL. Krogh Nielsen M, et al. Among authors: sorensen tl. Acta Ophthalmol. 2023 Dec;101(8):896-902. doi: 10.1111/aos.15794. Acta Ophthalmol. 2023. PMID: 37933609 Free article. Review.
Age-related macular degeneration: A two-level model hypothesis.
Rozing MP, Durhuus JA, Krogh Nielsen M, Subhi Y, Kirkwood TB, Westendorp RG, Sørensen TL. Rozing MP, et al. Among authors: sorensen tl. Prog Retin Eye Res. 2020 May;76:100825. doi: 10.1016/j.preteyeres.2019.100825. Epub 2019 Dec 30. Prog Retin Eye Res. 2020. PMID: 31899290 Review.
227 results